Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1995 Nov;59(5):457–459. doi: 10.1136/jnnp.59.5.457

The brain in obsessive-compulsive disorder.

P K McGuire
PMCID: PMC1073702  PMID: 8530924

Full text

PDF
457

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander G. E., DeLong M. R., Strick P. L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357–381. doi: 10.1146/annurev.ne.09.030186.002041. [DOI] [PubMed] [Google Scholar]
  2. Bastani B., Nash J. F., Meltzer H. Y. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Arch Gen Psychiatry. 1990 Sep;47(9):833–839. doi: 10.1001/archpsyc.1990.01810210041006. [DOI] [PubMed] [Google Scholar]
  3. Baxter L. R., Jr, Schwartz J. M., Bergman K. S., Szuba M. P., Guze B. H., Mazziotta J. C., Alazraki A., Selin C. E., Ferng H. K., Munford P. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992 Sep;49(9):681–689. doi: 10.1001/archpsyc.1992.01820090009002. [DOI] [PubMed] [Google Scholar]
  4. Baxter L. R., Jr, Schwartz J. M., Mazziotta J. C., Phelps M. E., Pahl J. J., Guze B. H., Fairbanks L. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry. 1988 Dec;145(12):1560–1563. doi: 10.1176/ajp.145.12.1560. [DOI] [PubMed] [Google Scholar]
  5. Benkelfat C., Nordahl T. E., Semple W. E., King A. C., Murphy D. L., Cohen R. M. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. Arch Gen Psychiatry. 1990 Sep;47(9):840–848. doi: 10.1001/archpsyc.1990.01810210048007. [DOI] [PubMed] [Google Scholar]
  6. Christensen K. J., Kim S. W., Dysken M. W., Hoover K. M. Neuropsychological performance in obsessive-compulsive disorder. Biol Psychiatry. 1992 Jan 1;31(1):4–18. doi: 10.1016/0006-3223(92)90003-i. [DOI] [PubMed] [Google Scholar]
  7. Cummings J. L., Cunningham K. Obsessive-compulsive disorder in Huntington's disease. Biol Psychiatry. 1992 Feb 1;31(3):263–270. doi: 10.1016/0006-3223(92)90049-6. [DOI] [PubMed] [Google Scholar]
  8. Eslinger P. J., Damasio A. R. Severe disturbance of higher cognition after bilateral frontal lobe ablation: patient EVR. Neurology. 1985 Dec;35(12):1731–1741. doi: 10.1212/wnl.35.12.1731. [DOI] [PubMed] [Google Scholar]
  9. Foote S. L., Morrison J. H. Extrathalamic modulation of cortical function. Annu Rev Neurosci. 1987;10:67–95. doi: 10.1146/annurev.ne.10.030187.000435. [DOI] [PubMed] [Google Scholar]
  10. Friston K. J., Grasby P. M., Bench C. J., Frith C. D., Cowen P. J., Liddle P. F., Frackowiak R. S., Dolan R. Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Neurosci Lett. 1992 Jul 6;141(1):106–110. doi: 10.1016/0304-3940(92)90345-8. [DOI] [PubMed] [Google Scholar]
  11. Garber H. J., Ananth J. V., Chiu L. C., Griswold V. J., Oldendorf W. H. Nuclear magnetic resonance study of obsessive-compulsive disorder. Am J Psychiatry. 1989 Aug;146(8):1001–1005. doi: 10.1176/ajp.146.8.1001. [DOI] [PubMed] [Google Scholar]
  12. Goodman W. K., McDougle C. J., Price L. H. Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry. 1992 Apr;53 (Suppl):29–37. [PubMed] [Google Scholar]
  13. Goodman W. K., Price L. H., Delgado P. L., Palumbo J., Krystal J. H., Nagy L. M., Rasmussen S. A., Heninger G. R., Charney D. S. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990 Jun;47(6):577–585. doi: 10.1001/archpsyc.1990.01810180077011. [DOI] [PubMed] [Google Scholar]
  14. Goodman W. K., Price L. H., Rasmussen S. A., Delgado P. L., Heninger G. R., Charney D. S. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989 Jan;46(1):36–44. doi: 10.1001/archpsyc.1989.01810010038006. [DOI] [PubMed] [Google Scholar]
  15. Head D., Bolton D., Hymas N. Deficit in cognitive shifting ability in patients with obsessive-compulsive disorder. Biol Psychiatry. 1989 Apr 1;25(7):929–937. doi: 10.1016/0006-3223(89)90272-2. [DOI] [PubMed] [Google Scholar]
  16. Hollander E., DeCaria C. M., Nitescu A., Gully R., Suckow R. F., Cooper T. B., Gorman J. M., Klein D. F., Liebowitz M. R. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992 Jan;49(1):21–28. doi: 10.1001/archpsyc.1992.01820010021003. [DOI] [PubMed] [Google Scholar]
  17. Hollander E., Schiffman E., Cohen B., Rivera-Stein M. A., Rosen W., Gorman J. M., Fyer A. J., Papp L., Liebowitz M. R. Signs of central nervous system dysfunction in obsessive-compulsive disorder. Arch Gen Psychiatry. 1990 Jan;47(1):27–32. doi: 10.1001/archpsyc.1990.01810130029005. [DOI] [PubMed] [Google Scholar]
  18. Hymas N., Lees A., Bolton D., Epps K., Head D. The neurology of obsessional slowness. Brain. 1991 Oct;114(Pt 5):2203–2233. doi: 10.1093/brain/114.5.2203. [DOI] [PubMed] [Google Scholar]
  19. Insel T. R., Murphy D. L., Cohen R. M., Alterman I., Kilts C., Linnoila M. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983 Jun;40(6):605–612. doi: 10.1001/archpsyc.1983.04390010015002. [DOI] [PubMed] [Google Scholar]
  20. Jenike M. A., Buttolph L., Baer L., Ricciardi J., Holland A. Open trial of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry. 1989 Jul;146(7):909–911. doi: 10.1176/ajp.146.7.909. [DOI] [PubMed] [Google Scholar]
  21. Jones A. K., Brown W. D., Friston K. J., Qi L. Y., Frackowiak R. S. Cortical and subcortical localization of response to pain in man using positron emission tomography. Proc Biol Sci. 1991 Apr 22;244(1309):39–44. doi: 10.1098/rspb.1991.0048. [DOI] [PubMed] [Google Scholar]
  22. Kellner C. H., Jolley R. R., Holgate R. C., Austin L., Lydiard R. B., Laraia M., Ballenger J. C. Brain MRI in obsessive-compulsive disorder. Psychiatry Res. 1991 Jan;36(1):45–49. doi: 10.1016/0165-1781(91)90116-7. [DOI] [PubMed] [Google Scholar]
  23. Laplane D., Levasseur M., Pillon B., Dubois B., Baulac M., Mazoyer B., Tran Dinh S., Sette G., Danze F., Baron J. C. Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions. A neuropsychological, magnetic resonance imaging and positron tomography study. Brain. 1989 Jun;112(Pt 3):699–725. doi: 10.1093/brain/112.3.699. [DOI] [PubMed] [Google Scholar]
  24. Leonard H. L., Swedo S. E., Lenane M. C., Rettew D. C., Hamburger S. D., Bartko J. J., Rapoport J. L. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry. 1993 Jun;50(6):429–439. doi: 10.1001/archpsyc.1993.01820180023003. [DOI] [PubMed] [Google Scholar]
  25. Lucey J. V., O'Keane V., Butcher G., Clare A. W., Dinan T. G. Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls. Br J Psychiatry. 1992 Oct;161:517–521. doi: 10.1192/bjp.161.4.517. [DOI] [PubMed] [Google Scholar]
  26. Luxenberg J. S., Swedo S. E., Flament M. F., Friedland R. P., Rapoport J., Rapoport S. I. Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. Am J Psychiatry. 1988 Sep;145(9):1089–1093. doi: 10.1176/ajp.145.9.1089. [DOI] [PubMed] [Google Scholar]
  27. Machlin S. R., Harris G. J., Pearlson G. D., Hoehn-Saric R., Jeffery P., Camargo E. E. Elevated medial-frontal cerebral blood flow in obsessive-compulsive patients: a SPECT study. Am J Psychiatry. 1991 Sep;148(9):1240–1242. doi: 10.1176/ajp.148.9.1240. [DOI] [PubMed] [Google Scholar]
  28. Marks I. M., Lelliott P., Basoglu M., Noshirvani H., Monteiro W., Cohen D., Kasvikis Y. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry. 1988 Apr;152:522–534. doi: 10.1192/bjp.152.4.522. [DOI] [PubMed] [Google Scholar]
  29. Martinot J. L., Allilaire J. F., Mazoyer B. M., Hantouche E., Huret J. D., Legaut-Demare F., Deslauriers A. G., Hardy P., Pappata S., Baron J. C. Obsessive-compulsive disorder: a clinical, neuropsychological and positron emission tomography study. Acta Psychiatr Scand. 1990 Sep;82(3):233–242. doi: 10.1111/j.1600-0447.1990.tb03059.x. [DOI] [PubMed] [Google Scholar]
  30. Mavissakalian M., Turner S. M., Michelson L., Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. Am J Psychiatry. 1985 May;142(5):572–576. doi: 10.1176/ajp.142.5.572. [DOI] [PubMed] [Google Scholar]
  31. McGuire P. K., Bench C. J., Frith C. D., Marks I. M., Frackowiak R. S., Dolan R. J. Functional anatomy of obsessive-compulsive phenomena. Br J Psychiatry. 1994 Apr;164(4):459–468. doi: 10.1192/bjp.164.4.459. [DOI] [PubMed] [Google Scholar]
  32. Mesulam M. M. A cortical network for directed attention and unilateral neglect. Ann Neurol. 1981 Oct;10(4):309–325. doi: 10.1002/ana.410100402. [DOI] [PubMed] [Google Scholar]
  33. Nordahl T. E., Benkelfat C., Semple W. E., Gross M., King A. C., Cohen R. M. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology. 1989 Mar;2(1):23–28. doi: 10.1016/0893-133x(89)90003-1. [DOI] [PubMed] [Google Scholar]
  34. Nyberg S., Farde L., Eriksson L., Halldin C., Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl) 1993;110(3):265–272. doi: 10.1007/BF02251280. [DOI] [PubMed] [Google Scholar]
  35. Pauls D. L., Towbin K. E., Leckman J. F., Zahner G. E., Cohen D. J. Gilles de la Tourette's syndrome and obsessive-compulsive disorder. Evidence supporting a genetic relationship. Arch Gen Psychiatry. 1986 Dec;43(12):1180–1182. doi: 10.1001/archpsyc.1986.01800120066013. [DOI] [PubMed] [Google Scholar]
  36. Perani D., Colombo C., Bressi S., Bonfanti A., Grassi F., Scarone S., Bellodi L., Smeraldi E., Fazio F. [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry. 1995 Feb;166(2):244–250. doi: 10.1192/bjp.166.2.244. [DOI] [PubMed] [Google Scholar]
  37. Perse T. L., Greist J. H., Jefferson J. W., Rosenfeld R., Dar R. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry. 1987 Dec;144(12):1543–1548. doi: 10.1176/ajp.144.12.1543. [DOI] [PubMed] [Google Scholar]
  38. Piccinelli M., Pini S., Bellantuono C., Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995 Apr;166(4):424–443. doi: 10.1192/bjp.166.4.424. [DOI] [PubMed] [Google Scholar]
  39. Poynton A., Bridges P. K., Bartlett J. R. Psychosurgery in Britain now. Br J Neurosurg. 1988;2(3):297–306. doi: 10.3109/02688698809000999. [DOI] [PubMed] [Google Scholar]
  40. Rauch S. L., Jenike M. A., Alpert N. M., Baer L., Breiter H. C., Savage C. R., Fischman A. J. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry. 1994 Jan;51(1):62–70. doi: 10.1001/archpsyc.1994.03950010062008. [DOI] [PubMed] [Google Scholar]
  41. Rauch S. L., Savage C. R., Alpert N. M., Miguel E. C., Baer L., Breiter H. C., Fischman A. J., Manzo P. A., Moretti C., Jenike M. A. A positron emission tomographic study of simple phobic symptom provocation. Arch Gen Psychiatry. 1995 Jan;52(1):20–28. doi: 10.1001/archpsyc.1995.03950130020003. [DOI] [PubMed] [Google Scholar]
  42. Rosen S. D., Paulesu E., Frith C. D., Frackowiak R. S., Davies G. J., Jones T., Camici P. G. Central nervous pathways mediating angina pectoris. Lancet. 1994 Jul 16;344(8916):147–150. doi: 10.1016/s0140-6736(94)92755-3. [DOI] [PubMed] [Google Scholar]
  43. Rubin R. T., Villanueva-Meyer J., Ananth J., Trajmar P. G., Mena I. Regional xenon 133 cerebral blood flow and cerebral technetium 99m HMPAO uptake in unmedicated patients with obsessive-compulsive disorder and matched normal control subjects. Determination by high-resolution single-photon emission computed tomography. Arch Gen Psychiatry. 1992 Sep;49(9):695–702. doi: 10.1001/archpsyc.1992.01820090023004. [DOI] [PubMed] [Google Scholar]
  44. Sawle G. V., Hymas N. F., Lees A. J., Frackowiak R. S. Obsessional slowness. Functional studies with positron emission tomography. Brain. 1991 Oct;114(Pt 5):2191–2202. doi: 10.1093/brain/114.5.2191. [DOI] [PubMed] [Google Scholar]
  45. Scarone S., Colombo C., Livian S., Abbruzzese M., Ronchi P., Locatelli M., Scotti G., Smeraldi E. Increased right caudate nucleus size in obsessive-compulsive disorder: detection with magnetic resonance imaging. Psychiatry Res. 1992 Aug;45(2):115–121. doi: 10.1016/0925-4927(92)90005-o. [DOI] [PubMed] [Google Scholar]
  46. Sher K. J., Frost R. O., Kushner M., Crews T. M., Alexander J. E. Memory deficits in compulsive checkers: replication and extension in a clinical sample. Behav Res Ther. 1989;27(1):65–69. doi: 10.1016/0005-7967(89)90121-6. [DOI] [PubMed] [Google Scholar]
  47. Swedo S. E., Pietrini P., Leonard H. L., Schapiro M. B., Rettew D. C., Goldberger E. L., Rapoport S. I., Rapoport J. L., Grady C. L. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch Gen Psychiatry. 1992 Sep;49(9):690–694. doi: 10.1001/archpsyc.1992.01820090018003. [DOI] [PubMed] [Google Scholar]
  48. Swedo S. E., Rapoport J. L., Cheslow D. L., Leonard H. L., Ayoub E. M., Hosier D. M., Wald E. R. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry. 1989 Feb;146(2):246–249. doi: 10.1176/ajp.146.2.246. [DOI] [PubMed] [Google Scholar]
  49. Swedo S. E., Schapiro M. B., Grady C. L., Cheslow D. L., Leonard H. L., Kumar A., Friedland R., Rapoport S. I., Rapoport J. L. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 1989 Jun;46(6):518–523. doi: 10.1001/archpsyc.1989.01810060038007. [DOI] [PubMed] [Google Scholar]
  50. Thorén P., Asberg M., Cronholm B., Jörnestedt L., Träskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry. 1980 Nov;37(11):1281–1285. doi: 10.1001/archpsyc.1980.01780240079009. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES